Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.
Non-Small Cell Lung Cancer
BIOLOGICAL: QBKPN SSI
Safety, tolerability and compliance variables, Assess the number of adverse events and subject reported data, 16 weeks
Exploratory variables, Assess and identify biomarkers associated with immune response, 16 weeks
Please refer to summary above.